Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Nasdaq leads Wall Street gains as Amazon rally offsets Apple decline
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Edwards Lifesciences Reports First Quarter Results
April 26, 2016 4:15 PM EDTIRVINE, Calif., April 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2016.
First Quarter Highlights:
Sales grew 18.1% to $697.3 million, and underlying1 sales were up 19.7% THVT sales grew 37.0%, and underlying sales were up 38.3% GAAP EPS was $0.66, an increase of 17.9%, and adjusted2 EPS grew 24.6% to $0.71 2016 sales guidance raised to $2.7 - $3.0 billion from $2.6 - $2.85... More